Acadian Asset Management’s Entrada Therapeutics TRDA Stock Holding History

Acadian Asset Management’s Portfolio TRDA Stock Details TRDA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.94M	Buy	400,862 +67,693	+20%	+$649K	﹤0.01%	954
2026 Q1	$4.2M	Buy	333,169 +22,336	+7%	+$256K	0.01%	757
2025 Q4	$3.19M	Buy	310,833 +12,890	+4%	+$109K	0.01%	782
2025 Q3	$1.72M	Buy	297,943 +252,137	+550%	+$1.48M	﹤0.01%	929
2025 Q2	$306K	Buy	45,806 +24,665	+117%	+$198K	﹤0.01%	1230
2025 Q1	$190K	Sell	21,141 -30,350	-59%	-$378K	﹤0.01%	1266
2024 Q4	$890K	Sell	51,491 -14,032	-21%	-$254K	﹤0.01%	947
2024 Q3	$1.04M	Buy	65,523 +52,156	+390%	+$822K	﹤0.01%	902
2024 Q2	$190K	Buy	13,367 +7,682	+135%	+$109K	﹤0.01%	1434
2024 Q1	$79K	Buy	+5,685	New	+$80.4K	﹤0.01%	1321

Other funds holding TRDA

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

5VM

5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Merck & Co Rahway, New Jersey $526M AUM 175.27% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

StepStone Group La Jolla, California $2.16B AUM 20.11% 1-Year Est. Return

Acadian Asset Management's TRDA Position: Q2 2026 in Review

Acadian Asset Management increased its Entrada Therapeutics (TRDA) stake by 20% in Q2 2026, buying an estimated $649K and bringing the position to 400,862 shares worth $2.94M. The position accounts for ﹤0.01% of the portfolio, ranked #954.

Acadian Asset Management first reported a position in TRDA in Q1 2024 and has held it in 10 quarters since. The position peaked at $4.2M in Q1 2026. 128 funds tracked by Wall St. Rank hold TRDA as of Q2 2026.

Acadian Asset Management held 400,862 shares of Entrada Therapeutics worth $2.94M as of Q2 2026.
Acadian Asset Management bought 67,693 Entrada Therapeutics shares in Q2 2026, an estimated $649K.
Entrada Therapeutics made up ﹤0.01% of Acadian Asset Management's portfolio in Q2 2026, its #954 holding.
Acadian Asset Management first reported a position in Entrada Therapeutics in Q1 2024 and has held it in 10 quarters since.
Acadian Asset Management's Entrada Therapeutics position peaked at $4.2M in Q1 2026.
128 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q2 2026.

Based on Acadian Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.